TearSolutions
Manufacturing · Virginia, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
315 Old Ivy Way Ste 301, Charlottesville...Phone Number
(434) 951-0444Website
www.tearsolutions.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About TearSolutions
TearSolutions specializes in developing innovative therapies for ocular surface diseases, notably through their proprietary peptide therapy, Lacripep. This first-in-class treatment aims to restore the health of the ocular surface by addressing deficiencies in tear proteins, particularly in patients suffering from conditions like primary Sjögren's Syndrome. The company targets individuals affected by dry eye disease, which is prevalent among older adults and exacerbated by environmental factors. With a strong leadership team and ongoing clinical trials, TearSolutions is positioned to make significant advancements in the field of ophthalmology.Explore more
TearSolutions Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TearSolutions your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once TearSolutions has new funding data
Check out if TearSolutions is spiking on competitors!
TearSolutions, which may be a good buyer, showed buying intent in Masked Content Topic
Check if TearSolutions has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when TearSolutions launches new products
Click to see if TearSolutions had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at TearSolutions
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on TearSolutions recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined TearSolutions as Masked Content
Find 3 more new buyers
Compare Similar Companies to TearSolutions
Compare insights from companies similar to TearSolutions, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
TearSolutions is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
TearSolutions is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about TearSolutions.
TearSolutions financials insights
Gather financial insights about TearSolutions, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$3M
2017
Private Equity
$3.4M
Private Equity
$8.1M
2019
Debt
$6.4M
2024
Series B
$3M
TearSolutions Tech Stack
A closer look at the technologies used by TearSolutions
See more technologies
Most Recent Scoops
Funding
Funding
Executive Move
Board of Directors
Promotion
Executive Move
Executive Move
Board of Directors
Executive Move
Board of Directors
TearSolutions News & Media
TearSolutions Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors
CHARLOTTESVILLE, Va., April 03, 2024 (GLOBE NEWSWIRE) — TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the... Read More The post TearSolutions Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors appeared first on citybiz.Sjogren's Syndrome Market Size Increase with Significant CAGR by 2032, Predicts DelveInsight | Key Companies in the Market - Resolve, MorphoSys, Novartis, GlaxoSmithKline, Roche, BMS, TearSolutions, Incyte, Galapagos, Gilead Sciences
Sjogren's syndrome market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies. Sjogren's syndrome market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch oTearSolutions Expands and Establishes Advisory Boards and Strengthens Leadership Team
CHARLOTTESVILLE, Va., March 07, 2023 (GLOBE NEWSWIRE) -- TearSolutions, Inc. a privately held clinical-stage ophthalmic biopharmaceutical company focused on developing a potentially disruptive therapy for the treatment of Dry Eye Disease (DED), called Lacripep, today announced that it has established a Strategic Advisory Board (SAB), appointed five Key Opinion Leaders (KOLs) with DED expertise to its Medical Advisory Board (MAB) and promoted James Cook to Chief Development Officer.TearSolutions, Inc. Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Lacripep™
CHARLOTTESVILLE, Va., Feb. 14, 2022 (GLOBE NEWSWIRE) -- TearSolutions, Inc. (“the Company”), a privately held developer of a replacement therapy for the treatment of Dry Eye Disease (DED) called Lacripep, today announced that in late 2021 it received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Lacripep for the treatment of keratoconjunctivitis sicca, also known as DED, and is planning to begin one of
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TearSolutions
Sign Up For FreeTo access detailed company insights
TearSolutions specializes in developing innovative therapies for ocular surface diseases, notably through their proprietary peptide therapy, Lacripep. This first-in-class treatment aims to restore the health of the ocular surface by addressing deficiencies in tear proteins, particularly in patients suffering from conditions like primary Sjögren's S... Read More
